Even poziotinib (HM781–36B), an irreversible EGFR inhibitor, has been studied in different clinical trials, showing efficacy in NSCLC [13] and in recurrent and/or metastatic head and neck SCC (R/M-HNSCC) [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.